Osteoporosis Therapy and Outcomes for Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer: NCIC CTG MA.27

    loading  Checking for direct PDF access through Ovid

Abstract

BACKGROUND:

Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of osteoporosis. This study examined the effects of self-reported osteoporosis and osteoporosis therapy (OPT) on outcomes.

METHODS:

The MA.27 phase 3 adjuvant trial enrolled 7576 postmenopausal women. The primary outcome was event-free survival (EFS), and the secondary outcome was distant disease–free survival (DDFS). Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis. In a multivariate, stratified Cox regression, factors were significant with a 2-sided Wald test P value ≤ .05.

RESULTS:

Osteoporosis was reported at the baseline by 654 of the 7576 women (8.6%) and in total by 1294 patients. Oral OPT was received at the baseline by 815 of the 7576 women (10.8%) and in total by 2711 patients (36%). With a median follow-up of 4.1 years, 693 EFS events (9.15%) and 321 DDFS events (4.2%) occurred. Osteoporosis was not associated with EFS or DDFS. Few EFS events occurred before the initiation of OPT, with no substantive evidence of a time-differing effect on outcomes (nonproportional hazards). OPT (yes vs no) was significantly associated with improved EFS (hazard ratio [HR] for yes vs no, 0.67; 95% confidence interval [CI], 0.57-0.80; P < .001) and DDFS (HR, 0.57; 95% CI, 0.44-0.73; P <. 001). Time-differing (time-dependent) OPT was not (EFS; P = .45). OPT did not alter the incidence of visceral-only metastasis (P = .31).

CONCLUSIONS:

Oral OPT, administered to postmenopausal breast cancer patients receiving adjuvant AI therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time-dependent effect) did not affect the outcome. OPT did not alter the risk of visceral metastasis.

Oral osteoporosis therapy, administered to postmenopausal breast cancer patients (n = 7576) receiving adjuvant aromatase inhibitor therapy (NCIC MA.27 trial), is associated with significantly improved event-free survival and distant disease–free survival; the time of initiation of osteoporosis therapy (a time-dependent effect) does not affect the outcome. Osteoporosis therapy does not alter the risk of visceral-only metastases.

See also pages 2392-4.

Related Topics

    loading  Loading Related Articles